Showing 1781-1790 of 2192 results for "".
- Ten-Year Data Demonstrate Ocrevus Treatment Reduced Disability in Individuals with Multiple Sclerosishttps://practicalneurology.com/news/ten-year-data-demonstrate-ocrevus-treatment-reduced-disability-in-individuals-with-multiple-sclerosis/2470444/According to long-term study results, earlier treatment with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in greater reductions in disability progression over 10 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) compa
- Ultrasound-Guided Lumbar Puncture Not Superior to Traditional Landmark-Based Approach According to Study at AAN 2024https://practicalneurology.com/news/ultrasound-guided-lumbar-puncture-not-superior-to-traditional-landmark-based-approach-according-to-study-at-aan-2024/2470441/Ultrasound guidance did not significantly affect the outcomes of lumbar puncture (LP) performed by a single experienced practitioner in the outpatient setting. According to data from the UltraGUD LP clinical trial (NCT03815045), which were presented at the American Academy of Neurology (AAN) 2024
- Dual Antiplatelet Therapy Superior to Aspirin Alone in Reducing Early Neurologic Deterioration in People with Mild-to-Moderate Ischemic Strokehttps://practicalneurology.com/news/dual-antiplatelet-therapy-superior-to-aspirin-alone-in-reducing-early-neurologic-deterioration-in-people-with-mild-to-moderate-ischemic-stroke/2470425/The use of combination therapy consisting of clopidogrel with aspirin was shown to be superior to aspirin alone in reducing early neurologic deterioration at 7 days for people who experienced a mild-to-moderate ischemic stroke. Clopidogrel with aspirin was also shown to have a similar safety prof
- Uplizna Safe and Effective for Adults Aged ≥50 Years with AQP4+ NMOSDhttps://practicalneurology.com/news/uplizna-safe-and-effective-for-adults-aged-50-years-with-aqp4-nmosd/2470418/People aged ≥50 years with aquaporin-4 antibody positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) who were treated with Uplizna (inebilizumab-cdon; Amgen, Dublin, Ireland) showed a reduced risk of attack compared with those receiving placebo, according to results of a post-hoc an
- MS Susceptibility Genes Introduced to Europe 5000 Years Ago According to Study Published in Naturehttps://practicalneurology.com/news/ms-susceptibility-genes-introduced-to-europe-5000-years-ago-according-to-study-published-in-nature/2470382/Genes associated with susceptibility for multiple sclerosis (MS) may have been introduced to Northern Europe 5000 years ago, according to new study results published in Nature. The study was conducted to investigate potential causes for the significantly greater prevalence of MS among Wh
- In Young Adults, Moderate-to-Heavy Drinking Linked to Higher Risk of Strokehttps://practicalneurology.com/news/in-young-adults-moderate-to-heavy-drinking-linked-to-higher-risk-of-stroke/2470059/According to a clinical study published in Neurology, people in their 20s and 30s who drink moderate to heavy amounts of alcohol may be more likely to have a stroke as young adults than people who drink low amounts or no alcohol. The more years that people drank moderately or heavily, the risk of
- FDA Gives 3-Month Extension of New Drug Application Review for Tofersen to Treat Superoxide Dismutase 1 Amyotrophic Lateral Sclerosishttps://practicalneurology.com/news/fda-gives-3-month-extension-of-new-drug-application-review-for-tofersen-to-treat-superoxide-dismutase-1-amyotrophic-lateral-sclerosis/2470052/The Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for tofersen (Biogen, Cambridge, MA) superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) treatment to April 25, 2023. Tofersen was evaluated in the phase 3 VALOR s
- Cognitive Decline Remains for Some 1 Year After Concussionhttps://practicalneurology.com/news/concussion-display-a-cognitive-decline-in-a-year-of-recovery/2469828/A new study published in Neurology, suggests individuals with mild traumatic brain injuries may be more likely to result in cognitive impairment, cognitive decline, or both 1 year later. O
- Yours, Truly--A Multicultural Storytelling Campaign--Launches to Bring Awareness to Nonmotor Symptoms of Parkinson Diseasehttps://practicalneurology.com/news/yours-truly-a-multicultural-storytelling-campaign-launches-to-bring-awareness-to-nonmotor-symptoms-of-parkinson-disease/2469763/A multicultural storytelling campaign, Yours, Truly , sharing the personal stories of people with Parkinson disease (PD), has launched. The aim of this campaign is to bring greater awareness and understanding of the nonmotor symptoms of PD
- Subcutaneous Foslevodopa/Foscarbidopa Superior at Controlling Motor Fluctuations in Parkinson Diseasehttps://practicalneurology.com/news/subcutaneous-foslevodopafoscarbidopa-superior-at-controlling-motor-fluctuations-in-parkinson-disease/2469731/In a phase 3 clinical trial, continuous subcutaneous infusion of foslevodopa/foscarbidopa (fosLD/fosCD) (ABBV-951; Abbvie, Chicago, IL) was statistically superior to oral levodopa/carbidopa (LD/CD) at reducing motor fluctuations in participants with advanced Parkinson disease (PD). "On"